Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for OA

Launched by THE FOUNDATION FOR ORTHOPAEDICS AND REGENERATIVE MEDICINE · Nov 29, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating the safety and effectiveness of a special type of stem cell therapy for people with osteoarthritis, which is a painful joint condition. The stem cells used in this study come from umbilical cords and are given to participants either through an injection directly into the joint or through an IV in the arm. The trial is currently recruiting participants of all genders who have been diagnosed with osteoarthritis and are willing to provide informed consent, meaning they understand the study and agree to take part.

To be eligible for this trial, participants should not have active infections, cancer, or serious health issues that could put them at risk. Pregnant women and those with certain medical conditions are also excluded. If you choose to participate, you will help researchers learn more about this potential treatment, and you will be closely monitored for any side effects or health changes during the study. This trial is an important step in exploring new options for managing osteoarthritis, and your involvement could contribute to future advancements in treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of Osteoarthritis
• • Understanding and willingness to sign a written informed consent document
• Exclusion Criteria:
• • Active infection
• • Active cancer
• • Chronic multisystem organ failure
• • Pregnancy
• • Clinically significant Abnormalities on pre-treatment laboratory evaluation
• • Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
• • Continued drug abuse
• • Pre-menopausal women not using contraception
• • Previous organ transplant
• • Hypersensitivity to sulfur